Greenstone, LLC

What Greenstone, LLC does

Greenstone, LLC was a generic pharmaceutical manufacturer that operated as a wholly-owned subsidiary of Pfizer Inc. before being spun off in November 2020 to form Viatris Inc. (NASDAQ: VTRS) alongside Pfizer's Upjohn business. Founded in 2012 (per company history records; firmographics also reference 1993 in a conflicting data point), the company specialized in producing off-patent equivalents of brand-name medications across multiple therapeutic categories, including Eplerenone (high blood pressure), Latanoprost (glaucoma), and Clindamycin phosphate (acne).

The company's core business centered on manufacturing and distributing cost-effective generic medicines to healthcare providers, pharmacies, and patients across the United States. Greenstone leveraged Pfizer's regulatory infrastructure, manufacturing capabilities, and established pharmaceutical distribution networks rather than operating proprietary technology platforms. Its value proposition rested on affordability — providing generic alternatives to higher-priced branded pharmaceuticals — rather than differentiated formulations or novel therapies.

Commercially, Greenstone operated as a horizontal market participant in generic pharmaceuticals with no publicly disclosed pricing model or revenue figures, as financials were consolidated into Pfizer's reporting during its subsidiary tenure. The company maintained a small headcount (11–50 employees) and was headquartered in Peapack, New Jersey. Its standalone operating existence ended in 2020 with the spin-off into Viatris, where its operations and product portfolio were absorbed. The entity was also implicated in federal antitrust litigation (2010–2014 period) alleging coordination with Sandoz on generic drug pricing, though Pfizer was ultimately dismissed from that case.

Name

Greenstone, LLC

Legal name

Greenstone, LLC

Website

https://greenstonellc.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

11–50 employees

Short description

Greenstone, LLC was a generic pharmaceutical manufacturer and wholly-owned subsidiary of Pfizer Inc., producing off-patent medications including treatments for hypertension, glaucoma, and acne. It was spun off into Viatris in November 2020.

Ownership category

akta.pro rank

Headquarters

HQ city

Peapack

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D

Core offering

Greenstone, LLC was a generic pharmaceutical manufacturer that produced and distributed off-patent prescription medications, including treatments for high blood pressure (Eplerenone), glaucoma (Latanoprost), and acne (Clindamycin phosphate). The company operated as a wholly-owned subsidiary of Pfizer Inc. and was absorbed into Viatris following the 2020 spin-off.

Product overview

Greenstone, LLC was a generic pharmaceutical company and former subsidiary of Pfizer. It specialized in manufacturing and distributing generic medicines. According to multiple sources, Greenstone was spun off from Pfizer in 2020 and became part of Viatris. The company produced generic versions of branded pharmaceuticals including treatments for high blood pressure, glaucoma, and acne. Specific generic products mentioned in litigation documents include Eplerenone, Latanoprost, and Clindamycin phosphate. No additional product catalog or technology product information was available in the provided source data.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and minor.

• PfizercoreStrategic or Co-development Partner · 1 January 2020Greenstone was a former subsidiary of Pfizer. Pfizer held ownership of Greenstone until it was spun off in 2020 into what became Viatris. Greenstone operated as Pfizer's generic drug manufacturing arm.
• SandozminorStrategic or Co-development PartnerGreenstone executives allegedly exchanged over 360 phone calls and texts with Sandoz counterparts to coordinate bids and customer allocation for six generic products. This relationship was the subject of antitrust litigation.

Recent moves5 records

Expansion highlights3 records

Direct peers

• Lupin Pharmaceuticals: India-based global generics manufacturer with a significant U.S. portfolio across cardiovascular, ophthalmology, and other chronic disease categories, comparable to Greenstone as an off-patent small-molecule player.
• Apotex: Largest Canadian-owned generic pharmaceutical manufacturer producing a wide range of off-patent prescription generics including cardiovascular and dermatology products, directly comparable to Greenstone's portfolio scope and business model.
• Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with a broad portfolio of off-patent small-molecule products across cardiovascular, ophthalmology, dermatology, and other chronic-disease categories overlapping Greenstone's mix.
• Dr. Reddy's Laboratories: India-based integrated global pharmaceutical manufacturer with a U.S. generics business spanning multiple therapeutic categories including cardiovascular and ophthalmology, comparable to Greenstone's portfolio breadth.
• Viatris: Global generics and specialty pharmaceutical company formed in 2020 by combining Pfizer's Upjohn business (including Greenstone) with Mylan. Greenstone's products and operations now sit directly within Viatris, making it the most direct functional comparable.
• Sandoz: Novartis's generics division and a major global manufacturer of off-patent small-molecule drugs; identified in court filings as the counterparty coordinating with Greenstone executives on six generic products. Directly comparable as an off-patent manufacturer across similar therapeutic categories.
• Sun Pharmaceutical Industries: India's largest specialty generic pharmaceutical company with a substantial U.S. generic portfolio (including dermatology and ophthalmology products), directly comparable as a generic manufacturer serving the same off-patent categories.
• Cipla: Major Indian generic pharmaceutical company with a sizable U.S. and global off-patent portfolio spanning respiratory, cardiovascular, and dermatology, offering comparable scale and therapeutic coverage to Greenstone.
• Aurobindo Pharma: Vertically integrated Indian generic manufacturer with a large U.S. and global off-patent product portfolio across cardiovascular, ophthalmic, and dermatology categories, directly comparable to Greenstone's therapeutic mix.

Broad incumbents

• Pfizer: Former parent company of Greenstone until the 2020 spinoff and a global pharmaceutical incumbent that retains an innovative-drug focus; comparable as the originator of many of the brands Greenstone genericized, but not a direct generics competitor post-spin.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/greenstone-llc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greenstone, LLC